Friday, October 13, 2017

Impact Biomedicines Raises $22M For Treating Myelofibrosis

San Diego-based Impact Biomedicines, a biopharmaceuticals startup targeting treatments for patients with myeloproliferative neoplasms and other cancers, has raised $22M in a funding round, the company said this morning. The Series A funding came from Medcxi. Impact Biomedicines says it was formed in 2016, after acquiring the full rights for global development and commercialization of the compound fedratinib from Sanofi. More information »